27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors
European Journal of Cancer Supplements（2006）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要